GCP
ALXN

GSA Capital Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

GSA Capital Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5,982
Closed -$537K – 1300
2020
Q1 		$537K Sell
5,982
-4,230
-41% -$415K 0.13% 139
2019
Q4 		$1.1M Sell
10,212
-6,388
-38% -$683K 0.13% 170
2019
Q3 		$1.63M Buy
+16,600
New +$1.87M 0.22% 41
2019
Q1 		– Sell
-43,500
Closed -$4.24M – 1792
2018
Q4 		$4.24M Buy
+43,500
New +$5.14M 0.49% 13
2018
Q3 		– Sell
-2,203
Closed -$274K – 2014
2018
Q2 		$274K Sell
2,203
-12,977
-85% -$1.52M 0.01% 1413
2018
Q1 		$1.69M Buy
+15,180
New +$1.81M 0.09% 368
2017
Q4 		– Sell
-3,836
Closed -$538K – 1917
2017
Q3 		$538K Buy
3,836
+1,482
+63% +$201K 0.04% 921
2017
Q2 		$286K Sell
2,354
-37,209
-94% -$4.33M 0.02% 1302
2017
Q1 		$4.8M Buy
39,563
+37,872
+2,240% +$4.88M 0.26% 19
2016
Q4 		$207K Sell
1,691
-16,591
-91% -$2.03M 0.01% 1582
2016
Q3 		$2.24M Buy
18,282
+5,090
+39% +$655K 0.12% 203
2016
Q2 		$1.54M Buy
13,192
+1,038
+9% +$147K 0.09% 367
2016
Q1 		$1.69M Buy
12,154
+4,955
+69% +$728K 0.11% 256
2015
Q4 		$1.37M Sell
7,199
-46,636
-87% -$8.15M 0.07% 475
2015
Q3 		$8.42M Buy
53,835
+50,750
+1,645% +$9.26M 0.41% 16
2015
Q2 		$558K Sell
3,085
-18,204
-86% -$3.14M 0.02% 1283
2015
Q1 		$3.69M Buy
21,289
+4,139
+24% +$749K 0.15% 102
2014
Q4 		$3.17M Buy
17,150
+4,062
+31% +$753K 0.22% 47
2014
Q3 		$2.17M Sell
13,088
-79,907
-86% -$13.1M 0.11% 176
2014
Q2 		$14.5M Buy
92,995
+75,127
+420% +$11.9M 0.65% 6
2014
Q1 		$2.72M Buy
+17,868
New +$2.84M 0.19% 99

Other funds holding ALXN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

GSA Capital Partners's ALXN Position: Q2 2020 in Review

GSA Capital Partners sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 5,982 shares — an estimated $537K sold.

GSA Capital Partners first reported a position in ALXN in Q1 2014 and held it in 21 quarters. The position peaked at $14.5M in Q2 2014. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

  • GSA Capital Partners reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • GSA Capital Partners sold 5,982 Alexion Pharmaceuticals shares in Q2 2020, an estimated $537K.
  • GSA Capital Partners first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 21 quarters.
  • GSA Capital Partners's Alexion Pharmaceuticals position peaked at $14.5M in Q2 2014.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on GSA Capital Partners's 13F filing for Q2 2020, filed 11 Aug 2020.